The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Vascular disrupting agents in clinical development
Open accessAbstract
Growth of human tumours depends on the supply of oxygen and nutrients via the surrounding vasculature. Therefore tumour vasculature is an attractive target for anticancer therapy. Apart from angiogenesis inhibitors that compromise the formation of new blood vessels, a second class of specific anticancer drugs has been developed. These so-called vascular disrupting agents (VDAs) target the established tumour vasculature and cause an acute and pronounced shutdown of blood vessels resulting in an almost complete stop of blood flow, ultimately leading to selective tumour necrosis. As a number of VDAs are now being tested in clinical studies, we will discuss their mechanism of action and the results obtained in preclinical studies. Also data from clinical studies will be reviewed and some considerations with regard to the future development are given.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640 · cited 1×
“Inhibiting angiogenesis has become a challenge in the development of a totally new class of anticancer drugs as was already acknowledged in 1971 by Folkman (1971).”
BackgroundClinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., & Chaplin, D. J. (1997) · PubMed · Cited by 622
Dowlati, A., Robertson, K., Cooney, M. M., Petros, W. P., Stratford, M. R. L., Jesberger, J. A., Rafie, N., Overmoyer, B. A., Makkar, V., Stambler, B. S., et al. (2002) · PubMed · Cited by 435
Tozer, G. M., Prise, V. E., Wilson, J., Locke, R. J., Vojnovic, B., Stratford, M. R. L., Dennis, M. F., & Chaplin, D. J. (1999) · PubMed · Cited by 323
3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon
Konerding, M. A., Fait, E., & Gaumann, A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1809 · Cited by 309
Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
Rustin, G. J. S., Galbraith, S. M., Anderson, H., Stratford, M., Folkes, L. K., Sena, L., Gumbrell, L., & Price, P. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.185 · Cited by 307
Stevenson, J. P., Rosen, M., Sun, W., Gallagher, M., Haller, D. G., Vaughn, D., Giantonio, B., Zimmer, R., Petros, W. P., Stratford, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.986 · Cited by 291
Differentiation and Definition of Vascular-Targeted Therapies
Siemann, D. W., Bibby, M. C., Dark, G. G., Dicker, A. P., Eskens, F. A. L. M., Horsman, M. R., Marmé, D., & LoRusso, P. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.416.11.2 · Cited by 272
Self-citationEndothelial cell proliferation as a novel approach to targeting tumour therapy
Denekamp, J. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.16 · Cited by 249
Vincent, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24586 · Cited by 242
ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
Davis, P. D., Dougherty, G. J., Blakey, D. C., Galbraith, S. M., Tozer, G. M., Holder, A. L., Naylor, M. A., Nolan, J., Stratford, M. R. L., Chaplin, D. J., et al. (2002) · PubMed · Cited by 231
Jameson, M. B., Thompson, P. I., Baguley, B. C., Evans, B. D., Harvey, V. J., Porter, D. J. T., McCrystal, M. R., Small, M., Bellenger, K., Gumbrell, L. A., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600992 · Cited by 136
Cooney, M. M., Radivoyevitch, T., Dowlati, A., Overmoyer, B. A., Levitan, N. I., Robertson, K., Levine, S. L., DeCaro, K., Buchter, C. M., Taylor, A. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0364-3 · Cited by 135
E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo
Ozawa, Y., Sugi, N. H., Nagasu, T., Owa, T., Watanabe, T., Koyanagi, N., Yoshino, H., Kitoh, K., & Yoshimatsu, K. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00275-1 · Cited by 132
Tumour vasculature as a target for cancer therapy.
Chaplin, D. J., & Dougherty, G. J. (1999) · PubMed · Cited by 129
Ching, L., Cao, Z., Kiéda, C., Zwain, S., Jameson, M. B., & Bc, B. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600368 · Cited by 123
Activity of flavone acetic acid (NSC-347512) against solid tumors of mice
Corbett, T. H., Bissery, M.-C., Wozniak, A., Plowman, J., Polin, L., Tapazoglou, E., Dieckman, J., & Valeriote, F. A. (1986) · Investigational New Drugs · doi:10.1007/bf00179586 · Cited by 122
Ramaswamy, B., ELIAS, A. D., Kelbick, N., Dodley, A., Morrow, M., Hauger, M., Allen, J., Rhoades, C. A., Kendra, K. L., Chen, H. X., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2603 · Cited by 116
Beerepoot, L. V., Radema, S. A., Witteveen, E. O., Thomas, T., Wheeler, C., Kempin, S. J., & Voest, E. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7458 · Cited by 115
Thomsen, L., Ching, L., Zhuang, L., Gavin, J. B., & Bc, B. (1991) · PubMed · Cited by 109
Rustin, G. J. S., Bradley, C., Galbraith, S. M., Stratford, M. R. L., Loadman, P. M., Waller, S., Bellenger, K., Gumbrell, L. A., Folkes, L. K., & Halbert, G. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600885 · Cited by 105
Beauregard, D. A., Thelwall, P., Chaplin, D. J., Hill, S., Adams, G., & Brindle, K. M. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.294 · Cited by 99
McGown, A. T., & Fox, B. W. (1989) · PubMed · Cited by 95
Koehne, C., Bajetta, E., Lin, E. H., Cutsem, E. V., Hecht, J. R., Douillard, J., Moore, M. J., Germond, C. J., Laurent, D., & Jacques, C. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3508 · Cited by 91
Tozer, G., Lewis, S., Michałowski, A., & Aber, V. R. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.46 · Cited by 89
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors
Siemann, D. W., & Shi, W. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.08.002 · Cited by 87
Hande, K. R., Hagey, A. E., Berlin, J. D., Cai, Y., MEEK, K., Kobayashi, H., Lockhart, A. C., Medina, D. M., Sosman, J. A., Gordon, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2159 · Cited by 81
Hori, K., Saito, S., & Kubota, K. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600296 · Cited by 75
Bc, B., Li, Z., & Kestell, P. (1997) · PubMed · Cited by 69
van Heeckeren, W. J., Bhakta, S., Ortiz, J., Duerk, J. L., Cooney, M. M., Dowlati, A., McCrae, K. R., & Remick, S. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8801 · Cited by 63
Preclinical studies of the novel vascular disrupting agent MN-029.
Shi, W., & Siemann, D. W. (2005) · PubMed · Cited by 37
Cited by
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Natural products: An evolving role in future drug discovery
Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 860
Endothelial Cell Heterogeneity
Aird, W. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006429 · Cited by 731
Tubulin-Interactive Natural Products as Anticancer Agents
Kingston, D. G. I. (2009) · Journal of Natural Products · doi:10.1021/np800568j · Cited by 328
Novel Agents on the Horizon for Cancer Therapy
Ma, W. W., & Adjei, A. A. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 304
Metadata
- Authors
- Hinnen, P., & Eskens, F. A. L. M.
- Venue
- British Journal of Cancer
- Published
- 2007-03-20
- Volume
- 96
- Issue
- 8
- Pages
- 1159-1165
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2088228460
- Cited by
- 263
- References
- 39
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.